Details of the Drug Combinations

General Information of This Drug (ID: DMZE2JO)

Drug Name

SNS-595 DMZE2JO

Synonyms

Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Ovarian cancer	2C73	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
SNS-595 + Panobinostat	DCUBJLX	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Azacitidine + SNS-595	DC87N20	Azacitidine	Myelodysplastic Syndromes	[4]
Decitabine + SNS-595	DC42X26	Decitabine	Leukemia	[5]
Azacitidine + SNS-595	DC4Z2WK	Azacitidine	Acute Myeloid Leukemia	[6]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01191801) Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (VALOR). U.S. National Institutes of Health.
2	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	ClinicalTrials.gov (NCT01913951) Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
5	ClinicalTrials.gov (NCT01893320) Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
6	ClinicalTrials.gov (NCT03338348) Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2